Oesophageal Cancer SSL

Professor Tim Underwood is the SSL for Oesophageal Cancer.

Importantly, a number of the workstreams are trainee led and all have significant trainee involvement.  Encouragingly, at consultant level a new cadre of young, research active upper GI surgeons are driving things forward.  Our initial efforts are focussed on understanding the current state of play in a number of areas through snap-shot audit and cohort studies.  These will hopefully develop in short order into interventional studies that the whole community can participate in. 

Tim Underwood

Heartburn Cancer UK

Supported by

Heartburn Cancer UK 


Total Neoadjuvant Treatment in Oesophageal Adenocarcinoma: The TNT OAC Trial

We are hoping to open a phase 2 trial comparing outcomes in patients with resectable oesophageal and gastro-oesophageal junction adenocarcinoma receiving two different total neoadjuvant treatment regimens early next year (TNT-OAC).  

Patients will receive either extended FLOT total neoadjuvant therapy or FLOT + CROSS total neoadjuvant therapy.  We will also be carrying out translational research on tissue from recruited patients.  More information can be found in the trial synopsis - click here to view more

We would be very grateful for your reply to the feasibility survey for the study at this link: https://www.surveymonkey.co.uk/r/TNT-OAC

Please do not hesitate to contact us if you have any questions. 

Best wishes,

Hollie Clements, Tim Underwood, Russell Petty 


RE: Pragmatic Randomisation of Oesophageal Cancer patients with Endoscopic ultraSound Staging (PROCESS).

PROCESS is a pragmatic randomised trial using a staging algorithm of CT and PET-CT followed by EUS, compared to CT and PET-CT alone, in the modern staging of oesophago-gastric adenocarcinoma to evaluate its clinical and cost effectiveness.

Click here to view the PROCESS Trial Schema

Click here to view the trial outline

We would like to gauge interest in this trial and above are links to a synopsis and schema for your review.  If there is sufficient interest we plan to submit the trial to the HTA for funding later in the year. The deadline for completion is the 30th August 2021.

Click here to complete the survey